S 3220
A bill to expand the tropical disease product priority review voucher program to encourage prevention and treatment of coccidioidomycosis.
Jurisdiction
US Congress
Session
118th Congress (2023-2024)
Last updated at
Jun 13, 2026, 2:02 PM
Take action
Sign in to record your position, submit testimony, or contact your legislator.
Sign in to take action- Introduced
- Passed Senate
- Passed House
- To President
- Became Law
Bill overview
This bill expands the priority-review voucher program for tropical diseases to include coccidioidomycosis (also known as Valley fever). A voucher entitles the holder to have a future new drug or biological product application acted upon by the Food and Drug Administration within six months.
Sponsors
Official sponsors from legislative records.
Primary sponsor
Cosponsors
Kyrsten Sinema
Arguments in favor
Reasons to support this legislation.
No arguments in favor have been submitted.
Submit yoursArguments opposed
Reasons to oppose this legislation.
No arguments opposed have been submitted.
Submit yoursRead the latest version inline or switch to a previous version.